| Name | Title | Contact Details |
|---|
Headquartered in Lexington, MA, iSpecimen offers an online marketplace for the purchase of human biospecimens, providing researchers with the specimens they need from the patients they want. The iSpecimen Marketplace connects healthcare organizations that have access to patients and specimens with the scientists who need them for their research and development projects. Proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. Researchers easily and compliantly gain access to specimens to drive scientific discovery. Partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. And ultimately, healthcare advances for all.
Nova Health Systems Inc is a Utica, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Great Plains Regional Medical Center is a North Platte, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Portal Instruments is transforming the delivery of modern medicines and enhancing the standard of care for chronic diseases. Portal`s unique platform technology is capable of injecting today`s new biological drugs, regardless of volume or viscosity, with minimal sensation and time, providing the patient with enabling connectivity to optimize their disease challenges. The computer-controlled delivery technology is silent, innocuous, and highly customizable across a large variety of medical, animal, agricultural, and cosmetic applications.
JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.